These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2516083)

  • 61. High-frequency transduction (HFT) of resistance to ceftazidime and other antibiotics by a wild-type Pseudomonas aeruginosa phage.
    Blahová J; Králiková K; Krcméry V; Mikovicová A
    Zentralbl Bakteriol; 1999 Apr; 289(2):179-83. PubMed ID: 10360318
    [No Abstract]   [Full Text] [Related]  

  • 62. The control of class I beta-lactamase expression in Enterobacteriaceae and Pseudomonas aeruginosa.
    Lodge JM; Piddock LJ
    J Antimicrob Chemother; 1991 Aug; 28(2):167-72. PubMed ID: 1778849
    [No Abstract]   [Full Text] [Related]  

  • 63. 'Covalent trapping' and latamoxef resistance in beta-lactamase-derepressed Pseudomonas aeruginosa.
    Livermore DM
    J Antimicrob Chemother; 1987 Jul; 20(1):7-13. PubMed ID: 3114214
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Current and future management of serious skin and skin-structure infections.
    Schwartz R; Das-Young LR; Ramirez-Ronda C; Frank E
    Am J Med; 1996 Jun; 100(6A):90S-95S. PubMed ID: 8678103
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of the E test and microdilution for detection of beta-lactam-resistant mutants that are stably derepressed for type I beta-lactamase.
    Knapp CC; Washington JA
    J Clin Microbiol; 1992 Jan; 30(1):214-5. PubMed ID: 1734054
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antimicrobial activity of FK-037 against class I beta-lactamase producing species resistant to ceftazidime: a multi-laboratory clinical isolate sample.
    Sanchez ML; Jones RN
    J Antimicrob Chemother; 1993 Oct; 32(4):654-6. PubMed ID: 8288510
    [No Abstract]   [Full Text] [Related]  

  • 67. Comment on: An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa.
    Nicolau DP; Bhagwat SS; Abdelraouf K
    J Antimicrob Chemother; 2021 Nov; 76(12):3326-3327. PubMed ID: 34179957
    [No Abstract]   [Full Text] [Related]  

  • 68. Diffusion disk susceptibility testing with cefotaxime.
    Aswapokee N; Aswapokee P; Neu HC; Fu KP
    Antimicrob Agents Chemother; 1979 Aug; 16(2):164-6. PubMed ID: 114106
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa--authors' response.
    Isler B; Harris P; Stewart AG; Paterson DL
    J Antimicrob Chemother; 2021 Nov; 76(12):3327-3328. PubMed ID: 34624086
    [No Abstract]   [Full Text] [Related]  

  • 70. Comparative in vitro susceptibility of Burkholderia Pseudomallei to cefpirome, ceftazidime and cefepime.
    Seymour-Murray J; Norton R; Ashhurst-Smith C
    Pathology; 1997 Aug; 29(3):329-30. PubMed ID: 9271030
    [No Abstract]   [Full Text] [Related]  

  • 71. Heterogeneity of class I beta-lactamase expression in clinical isolates of Pseudomonas aeruginosa.
    Sanders CC; Gates ML; Sanders WE
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1893-5. PubMed ID: 3149885
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Stability and antibacterial activity of cefepime during continuous infusion.
    Sprauten PF; Beringer PM; Louie SG; Synold TW; Gill MA
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1991-4. PubMed ID: 12760882
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Characterization of cefsulodin-resistant variants of Pseudomonas aeruginosa.
    Slack MP; Pitt TL
    J Antimicrob Chemother; 1982 Feb; 9(2):111-7. PubMed ID: 6801005
    [No Abstract]   [Full Text] [Related]  

  • 74. Ceftazidime resistance in Hafnia alvei.
    Thomson KS; Sanders CC; Washington JA
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1375-6. PubMed ID: 8328790
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In vitro activity of the two new oral cephalosporins RO 15-8074 and RO 19-5247.
    Stobberingh E; Houben AW; van Boven CP
    Eur J Clin Microbiol; 1987 Aug; 6(4):489-90. PubMed ID: 3665902
    [No Abstract]   [Full Text] [Related]  

  • 76. Effect of serum from different patient populations on the serum bactericidal test.
    Kays MB; White RL; Friedrich LV
    J Antimicrob Chemother; 2001 Sep; 48(3):417-20. PubMed ID: 11533009
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In vitro activity of cefpodoxime, a new oral cephalosporin.
    Stobberingh EE; Houben AW; Philips JH
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):656-8. PubMed ID: 2506031
    [No Abstract]   [Full Text] [Related]  

  • 78. Properties of the beta-lactamase specified by the Pseudomonas plasmid RPL11.
    Matthew M; Sykes RB
    J Bacteriol; 1977 Oct; 132(1):341-5. PubMed ID: 410783
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A three category system for interpretation of disk tests for Pseudomonas-active penicillins and beta-lactamase hydrolysis/inhibition studies.
    Barry AL; Jones RN
    J Antimicrob Chemother; 1982 Jan; 9 Suppl A():35-45. PubMed ID: 6804432
    [No Abstract]   [Full Text] [Related]  

  • 80. In vitro selective concentrations of cefepime and ceftazidime for AmpC beta-lactamase hyperproducer Enterobacter cloacae variants.
    Negri MC; Baquero F
    Clin Microbiol Infect; 1998; 4(10):585-588. PubMed ID: 11864247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.